Drug Profile
MDNA 413
Alternative Names: Fc-MDNA413; MDNA-413Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Medicenna Therapeutics; Stanford University
- Class Antineoplastics; Cytokines; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 4 receptor type II antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Atopic dermatitis; Solid tumours
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 22 Sep 2022 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 10th Annual Meeting of the International Cytokine & Interferon Society (Cytokines-2022)
- 08 Apr 2022 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022) .